Androgen Deprivation Therapy and SARS-CoV-2 Infection in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis
Hüseyin Salih Semiz1, Mehmet Emin Arayici2, Hulya Ellidokuz31Department of Medical Oncology, Dokuz Eylul University, Institute of Oncology, Izmir, Türkiye, 2Department of Preventive Oncology, Dokuz Eylul University, Institute of Health Sciences, Izmir, Türkiye, 3Department of Preventive Oncology, Dokuz Eylul University, Institute of Oncology, Izmir, Türkiye
Objectives: The main treatment for metastatic prostate cancer is androgen deprivation therapy. The relationship between ADT and SARSCoV-2 virus was intensively investigated since the COVID 19 pandemic began. To perform a metaanalysis to evaluate the effect of androgen deprivation therapy (ADT) on COVID-19 in patients with prostate cancer. Methods: On January 11th, a comprehensive literature search was conducted following PRISMA guidelines in the PubMed, Scopus, Embase, and Web of Science databases, and an update was conducted on January 24 for this search. Results: Eight papers were included for systematic review. Five studies were suitable for meta-analysis. The incidence of SARS-CoV-2 infection among patients who were receiving ADT was 3.0%. ADT was not associated with a lower incidence of SARS-CoV-2 infection (95% CI: 0.56-1.58, RR = 0.94, p=.91; I2 = 60%, p=.03). Mortality was around 28% and there was no significant relationship between ADT use and mortality (95% CI: 0.61-1.69, RR = 1.01, p=.96). Conclusion: It is difficult to say that there is a relationship between use of ADT and the risk of death due to COVID-19 infection. But there is also no evidence to suggest that ADT causes the risk of death from COVID-19. Keywords: Androgen deprivation therapy, prostate cancer, SARS-CoV-2
Cite This Article
Semiz H, Arayici M, Ellidokuz H. Androgen Deprivation Therapy and SARS-CoV-2 Infection in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis. EJMI. 2022; 6(3): 273-278
Corresponding Author: Hüseyin Salih Semiz